Welcome to Markets Desk, your midday read on what's moving markets and why.
Eli Lilly scored a meaningful regulatory win today as the FDA granted full approval to Inluriyo in combination with Verzenio for ESR1-mutated breast cancer. That's a combination of an oral estrogen receptor antagonist paired with Lilly's established CDK4/6 inhibitor, expanding the company's oncology footprint and reinforcing its position as a dominant force in targeted cancer therapy.
Shifting to fixed income and its ripple effects, a closer look at insurance stocks in a rising rate environment tells an interesting story. Historically, insurers benefit from higher bond yields because their investment portfolios, heavily weighted toward fixed income, generate more income as rates climb. With the Fed continuing its tightening cycle, that tailwind is worth watching closely.
And in the ETF space, a new breed of so-called autocallable funds is drawing attention with advertised yields as high as seventeen and a half percent. The catch is significant — these instruments behave like bonds on the surface but carry direct exposure to equity risk, meaning investors chasing that headline yield could face sharp principal losses if underlying markets turn against them.
That's the tape. Markets Desk, signing off the floor.
